Safety study of CT1182 for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell non-Hodgkin lymphoma that has relapsed (returned) or become resistant to prior treatment
- You previously received standard chemotherapy including anti-CD20 drugs and anthracyclines
- Your cancer is measurable on CT scan or PET scan
- Your heart, liver, and kidney function meet certain minimum levels
- You have not received other experimental cell therapies or CD19-targeted treatments recently
- You are 18–75 years old with expected survival of at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called CT1190B for people with large B-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The goal is to see if this treatment can help shrink or control the cancer.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
This study tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that came back or did not improve after other treatments. The therapy uses your own immune cells to fight the cancer, and the study aims to see if it is safe and effective.
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
This trial tests a new treatment called CT1194C for patients with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two previous treatments. It aims to see if this treatment can help control the lymphoma and is safe.
Hear when a new B-cell Non Hodgkin Lymphoma (NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.